Skip to main content
Article thumbnail
Location of Repository

Stem cells for enhancing recovery after stroke: a review

By Timothy J. England, Paul Martin and Philip M.W. Bath


The potential application for stem cell therapy is vast, and\ud development for use in ischaemic stroke is still in its infancy. Access to stem cells for research is contentious; however, stem cells are obtainable from both animal and human. Despite a limited understanding of their mechanisms of action, clinical trials assessing stem cells in human stroke have been performed. Trials are also underway evaluating haematopoietic precursors mobilised with granulocyte-colony stimulating factor, an approach offering an autologous means of administrating stem cells for therapeutic purposes. This review summarises current knowledge in regard to stem cells and their potential for helping improve recovery after stroke

Year: 2009
OAI identifier:
Provided by: Nottingham ePrints

Suggested articles


  1. A conditionally immortal clonal stem cell line from human cortical neuroepithelium for the treatment of ischemic stroke.
  2. A neuroprotective function for the hematopoietic protein granulocyte-macrophage colony stimulating factor (GM-CSF).
  3. (2006). A Short-Term Assessment of Recombinant Granulocyte-Stimulating factor (RHG-CSF) in Treatment of Acute Cerebral Infarction. Cerebrovascular Diseases
  4. ABC of arterial and venous disease. Acute stroke. doi
  5. Activated neural stem cells contribute to stroke-induced neurogenesis and neuroblast migration toward the infarct boundary in adult rats.
  6. Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model.
  7. Adult bone marrow stromal cells differentiate into neural cells in vitro.
  8. (2001). Adult bone marrow transplantation after stroke in adult rats.
  9. (2005). An apology: inadvertent error in our article published in
  10. (1998). Analysis of rhG-CSF-effects on platelets by in vitro bleeding test and transcranial Doppler ultrasound examination.
  11. Anti-inflammatory effects of human cord blood cells in a rat model of stroke.
  12. Anti-inflammatory mechanism of intravascular neural stem cell transplantation in haemorrhagic stroke.
  13. Autologous mesenchymal stem cell transplantation in stroke patients.
  14. Autologous mesenchymal stem cell transplantation in stroke patients.[comment]. Annals of Neurology 2005;58(4):653-4; author reply
  15. Beneficial effects of hematopoietic growth factor therapy in chronic ischemic stroke in rats.
  16. Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion.
  17. CD34- hematopoietic stem cells: current concepts and controversies.
  18. Central nervous system entry of peripherally injected umbilical cord blood cells is not required for neuroprotection in stroke.
  19. Circulating CD34-positive cells provide an index of cerebrovascular function.
  20. Clonal human (hNT) neuron grafts for stroke therapy: neuropathology in a patient 27 months after implantation.
  21. (1993). Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus.
  22. (2006). Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke. Cochrane Database of Systematic Reviews
  23. Comparison of ischemia-directed migration of neural precursor cells after intrastriatal, intraventricular, or intravenous transplantation in the rat.
  24. Contradicted and initially stronger effects in highly cited clinical research.
  25. Crossed cerebellar diaschisis. Further studies.
  26. Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age.
  27. Differential properties of adult rat and mouse brain-derived neural stem/progenitor cells.
  28. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials.[see comment]. doi
  29. (2004). Effects of GCSF in combination with rt-PA after experimental thromboembolic stroke. Akt Neurol
  30. Endogenous neurogenesis in the human brain following cerebral infarction.
  31. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury.
  32. Evidence for neurogenesis in the adult mammalian substantia nigra.
  33. (2002). Excitatory amino acid antagonists for acute stroke (Cochrane Review). In: The Cochrane Library.
  34. Exploitation of adherent neural stem cells in basic and applied neurobiology. doi
  35. Failure of bone marrow cells to transdifferentiate into neural cells in vivo.
  36. Fiblast (Trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial.
  37. Functional recovery of stroke rats induced by granulocyte colony-stimulating factor-stimulated stem cells.
  38. G-CSF and rt-PA for the treatment of Experimental Embolic Stroke. Cerebrovascular Diseases 2007;23(Suppl 2):23.
  39. G-CSF reduces infarct volume and improves functional outcome after transient focal cerebral ischemia in mice.
  40. G-CSF suppresses edema formation and reduces interleukin-1beta expression after cerebral ischemia in mice.
  41. Granulocyte colony-stimulating factor enhances angiogenesis after focal cerebral ischemia.
  42. Granulocyte colony-stimulating factor for acute ischemic stroke: a randomized controlled trial.
  43. Granulocyte colony-stimulating factor has a negative effect on stroke outcome in a murine modelwa.
  44. Granulocyte-colony-stimulating factor mobilizes bone marrow stem cells in patients with subacute ischemic stroke: the Stem cell Trial of recovery EnhanceMent after Stroke (STEMS) pilot randomized, controlled trial (ISRCTN 16784092).
  45. Host-dependent tumorigenesis of embryonic stem cell transplantation in experimental stroke.
  46. Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats.
  47. Human cord blood CD34+ cells and behavioral recovery following focal cerebral ischemia in rats.
  48. Human neural stem cells improve sensorimotor deficits in the adult rat brain with experimental focal ischemia. doi
  49. Human neural stem/progenitor cells, expanded in long-term neurosphere culture, promote functional recovery after focal ischemia in Mongolian gerbils.
  50. Human umbilical cord blood cells do not improve sensorimotor or cognitive outcome following transient middle cerebral artery occlusion in rats.
  51. Identification of neuronal outgrowth cells from peripheral blood of stroke patients.
  52. In vitro neurogenesis by progenitor cells isolated from the adult human hippocampus.
  53. Infusion of human umbilical cord blood cells in a rat model of stroke dose-dependently rescues behavioral deficits and reduces infarct volume.
  54. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies.
  55. Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats.
  56. Intrinsic differences distinguish transiently neurogenic progenitors from neural stem cells in the early postnatal brain. doi
  57. Ischemic preconditioning enhances neurogenesis in the subventricular zone.
  58. Isolation and characterization of neural stem cells from the adult human olfactory bulb. doi
  59. (2006). Isolation of neuronal progenitor cells from the adult human neocortex.
  60. License to run: exercise impacts functional plasticity in the intact and injured central nervous system by using neurotrophins.
  61. Limitations of intravenous human bone marrow CD133+ cell grafts in stroke rats.
  62. Little evidence for developmental plasticity of adult hematopoietic stem cells.[see comment].
  63. Macrophage colony stimulating factor prevents NMDA-induced neuronal death in hippocampal organotypic cultures.
  64. Magnetic resonance tracking of human CD34 progenitor cells separated by means of immunomagnetic selection and transplanted into injured rat brain.
  65. Mapping transplanted stem cell migration after a stroke: a serial, in vivo magnetic resonance imaging study. doi
  66. migration and neuronal differentiation of human fetal striatal and cortical neural stem cells grafted in stroke-damaged rat striatum. doi
  67. Mobilization of CD34+ hematopoietic cells, colony-forming cells and long-term culture-initiating cells into the peripheral blood of patients with an acute cerebral ischemic insult.
  68. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction.
  69. Monitoring of implanted stem cell migration in vivo: a highly resolved in vivo magnetic resonance imaging investigation of experimental stroke in rat.
  70. Multilineage potential of stable human mesenchymal stem cell line derived from fetal marrow.
  71. (1999). Multipotent stem/progenitor cells with similar properties arise from two neurogenic regions of adult human brain. doi
  72. Neurogenesis by progenitor cells in the ischemic adult rat hippocampus.
  73. Neurogenesis in dentate subgranular zone and rostral subventricular zone after focal cerebral ischemia in the rat.
  74. (1998). Neurogenesis in the adult human hippocampus.
  75. Neurological and functional recovery in human stroke are associated with peripheral blood CD34+ cell mobilization.
  76. Neuronal differentiation of transplanted embryonic stem cell-derived precursors in stroke lesions of adult rats. doi
  77. Neuronal replacement from endogenous precursors in the adult brain after stroke. doi
  78. Neuroprotective effect of granulocyte colony-stimulating factor after focal cerebral ischemia.
  79. Neuroprotective effect of recombinant human granulocyte colony-stimulating factor in transient focal ischemia of mice.
  80. Neurotransplantation for patients with subcortical motor stroke: a phase 2 randomized trial.
  81. Neurotransplantation of fetal porcine cells in patients with basal ganglia infarcts: a preliminary safety and feasibility study.
  82. No evidence for infection of human cells with porcine endogenous retrovirus (PERV) after exposure to porcine fetal neuronal cells.
  83. Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner.
  84. Other neuroprotective therapies on trial in acute stroke. doi
  85. (2005). Pharmacological enhancement of recovery from stroke. Current Medical Literature Stroke Review
  86. Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2. Differentiation in vivo and in vitro.
  87. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). doi
  88. Potentiation of neurogenesis and angiogenesis by GCSF after focal cerebral ischemia in rats.
  89. (1999). Recommendations for standards regarding preclinical neuroprotective and restorative drug development.
  90. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair.
  91. ReNeuron Group plc.
  92. (1991). Reshaping the cortical motor map by unmasking latent intracortical connections.
  93. Safety and efficacy study of autologous stem cell transplantation for early onset Type I Diabetes Mellitus.
  94. SDF-1alpha/CXCR4-mediated migration of systemically transplanted bone marrow stromal cells towards ischemic brain lesion in a rat model.
  95. (2004). Skeletal stem cells.
  96. Stem cell factor stimulates neurogenesis in vitro and in vivo.
  97. stem cell transplant in treating patients with hematological cancer.
  98. Stem cell transplantation for Huntington's disease.
  99. Stemness": Definitions, Criteria and Standards.
  100. (2007). Stroke Unit Trialists C. Organised inpatient (stroke unit) care for stroke. Cochrane Database of Systematic Reviews.
  101. Synchronous neuronal activity is a signal for axonal sprouting after cortical lesions in the adult.
  102. Systemic transplantation of human adipose stem cells attenuated cerebral inflammation and degeneration in a hemorrhagic stroke model.
  103. The ATLANTIS ECASS and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. doi
  104. The effect of granulocytecolony stimulating factor in global cerebral ischemia in rats.
  105. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis.
  106. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats.
  107. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor.
  108. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. doi
  109. (1997). Transfectable and transplantable postmitotic human neurons: a potential "platform" for gene therapy of nervous system diseases.
  110. Transplantation of a novel cell line population of umbilical cord blood stem cells ameliorates neurological deficits associated with ischemic brain injury.
  111. Transplantation of cultured human neuronal cells for patients with stroke.
  112. Transplantation of embryonic dopamine neurons for severe Parkinson's disease.
  113. Transplantation of embryonic porcine mesencephalic tissue in patients with PD.
  114. Transplantation of embryonic stem cells overexpressing Bcl2 promotes functional recovery after transient cerebral ischemia. doi
  115. Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex.
  116. Transplanted human neurons derived from a teratocarcinoma cell line (NTera-2) mature, integrate, and survive for over 1 year in the nude mouse brain.
  117. Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.